Mostrar el registro sencillo del ítem
Anticoagulación oral en el adulto mayor frágil con fibrilación auricular
dc.contributor.author | Cadena Sanabria, Miguel Oswaldo | spa |
dc.contributor.author | Pinto Saavedra, Oscar Mariano | spa |
dc.contributor.author | Contreras Valero, Juan Fernando | spa |
dc.contributor.author | Ortega Ramírez, Gustavo Eduardo | spa |
dc.contributor.author | Bautista Mier, Heider Alexis | spa |
dc.date.accessioned | 2020-10-27T14:19:37Z | |
dc.date.available | 2020-10-27T14:19:37Z | |
dc.date.issued | 2017-08-03 | |
dc.identifier.issn | 2382-4603 | |
dc.identifier.issn | 0123-7047 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/10006 | |
dc.description.abstract | El envejecimiento incrementa el riesgo de trombosis y fenómenos embólicos, trae cambios fisiológicos y comorbilidades como la fibrilación auricular que hacen complejo el inicio y la seguridad de la anticoagulación. A pesar de la mayor disponibilidad de clínicas de anticoagulación y nuevos anticoagulantes orales, es bajo el porcentaje de adultos mayores que están anticoagulados aunque tengan indicación plena y ausencia de contraindicaciones. Objetivo: Revisar las principales estrategias para predecir y disminuir el riesgo de sangrado con el empleo de anticoagulantes orales en pacientes adultos mayores frágiles. Metodología: Se realizó una búsqueda sistemática sobre estudios que evaluaran la seguridad y eficacia de anticoagulantes orales en pacientes con fibrilación auricular en adultos mayores de 65 años, y una búsqueda de estudios sobre el síndrome de fragilidad y su impacto en el adulto mayor anticoagulado. Resultados y Discusión: Se ha denominado fragilidad al porcentaje de adultos mayores que presentan un mayor deterioro de sus sistemas biológico, físico y cognitivo, conduciendo a una mayor probabilidad de desenlaces adversos en salud, discapacidad y muerte. Se han estudiado características clínicas que permiten identificar pacientes como frágiles; el fenotipo de fragilidad de Linda Fried evalúa esas características; además, existen estrategias de monitoreo de los anticoagulantes orales que deben ser conocidos para minimizar el riesgo de eventos adversos. Conclusiones: el anciano frágil presenta factores de riesgo que probablemente afectan la eficacia y seguridad de la terapia con anticoagulantes orales. Las guías clínicas existentes no proveen la suficiente evidencia y no consideran de manera multidimensional al paciente geriátrico. | spa |
dc.format.mimetype | application/pdf | spa |
dc.format.mimetype | Application/vnd.openxmlformats-officedocument.wordprocessingml.document | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/2273/2303 | |
dc.relation | Https://revistas.unab.edu.co/index.php/medunab/article/view/2273/2724 | |
dc.relation.uri | https://revistas.unab.edu.co/index.php/medunab/article/view/2273 | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.source | MedUNAB; Vol. 19 Núm. 3 (2017): Diciembre - Marzo de 2017: Intento Suicida, Úlceras Corneales, Anticoagulación Oral; 221-229 | |
dc.title | Anticoagulación oral en el adulto mayor frágil con fibrilación auricular | |
dc.title.translated | Oral anticoagulants in the frail elderly with atrial fibrillation | eng |
dc.title.translated | Anticoagulação oral nas pessoas idosas com fibrilhação auricular | port |
dc.publisher.faculty | Facultad Ciencias de la Salud | |
dc.publisher.program | Pregrado Medicina | |
dc.type.driver | info:eu-repo/semantics/article | |
dc.type.local | Artículo | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | |
dc.subject.keywords | Atrial fibrillation | |
dc.subject.keywords | Frail old man | |
dc.subject.keywords | Anticoagulants | |
dc.subject.keywords | Side effects | |
dc.subject.keywords | Drug-related reactions | |
dc.subject.keywords | Geriatrics | |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga UNAB | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | Sheikh A, Patel NJ, Nalluri N, Agnihotri K, Spagnola J, Patel A, Asti D, Kanotra R, Khan H, Savani C, Arora S, PatelN,ThakkarB,PatelN,PauD,BadhekaAO, Deshmukh A, Kowalski M, Viles-Gonzalez J, Paydak H. Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. Prog Cardiovasc Dis 2015; 58(2):105-116. Doi: 10.1016/j.pcad.2015.07.002 | |
dc.relation.references | WielochM,SjälanderA,FrykmanV,RosenqvistM, ErikssonN,SvenssonPJ.Anticoagulationcontrolin Sweden:reportsoftimeintherapeuticrange,major bleeding, and thrombo-embolic complications from the nationalqualityregistryAuriculA.EurHeartJ2011; 32(18):2282-2289. Doi: 10.1093/eurheartj/ehr134 | |
dc.relation.references | Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: Anet clinical benefit analysis using a 'real world nationwidecohortstudy.ThrombHaemost2011; 106(4):739-749. Doi: 10.1160/TH11-05-0364 | |
dc.relation.references | Clegg A, Young J, Iliffe S, Olde-Rikkert MGM, Rockwood K. Frailty in Older People. Lancet 2013; 381(9868):752-762. Doi:10.1016/S0140-6736(12)62167-9 | |
dc.relation.references | Rodríguez-MañasL,FriedLP.Frailtyintheclinical scenario.Lancet2014;385(9968):e7-e9.Doi: 10.1016/S0140-6736(14)61595-6 | |
dc.relation.references | Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group. Frailty in Older Adults: Evidence for a Phenotype.JGerontolABiolSciMedSci2001; 56A(3):M146-156. Doi: 10.1093/gerona/56.3.M146 | |
dc.relation.references | Gómez-MontesJF,Curcio-BorreroCL,HenaoGM. Fragilidad en ancianos Colombianos. Rev Medica.Sanitas 2012; 15(4): 8-16 | |
dc.relation.references | Cadena-Sanabria MO, Rodríguez-Arrieta LA, Gallego-Andrade RG. Escala Identification of Seniors at Risk (ISAR):herramienta para la predicción de eventos adversos en el departamento de Urgencias. Rev Asoc Colomb Gerontol Geriatr 2013; 27(4):1887-1896 | |
dc.relation.references | McCusker J, Bellavance F, Cardin S, Trépanier S, Verdon J, Ardman O. Detection of older people at increased risk of adverse health outcomes after an emergency visit: the ISARscreening tool. J Am Geriatr Soc 1999; 47(10):1229-1237. Doi: 10.1111/j.1532-5415.1999.tb05204.x | |
dc.relation.references | Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38(2):156-162. Doi: 10.1093/ageing/afn293 | |
dc.relation.references | Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, GoAS,SingerDE.Advancedage,anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141(10):745-752. Doi: 10.7326/0003-4819-141-10-200411160-00005 | |
dc.relation.references | Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associatedhemorrhage:theanticoagulationandrisk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54(8):1231-1236. Doi: 10.1111/j.1532-5415.2006.00828.x | |
dc.relation.references | Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003;120(3)526-528 | |
dc.relation.references | Gage BF, Birman-Deych E, Kerzner R, Radford MJ, NilasenaDS,RichMW.Incidenceofintracranial hemorrhage in patients with atrial fibrillation who are prone tofall.AmJMed2005;118(6):612-617.Doi: 10.1016/j.amjmed.2005.02.022 | |
dc.relation.references | RosandJ,EckmanMH,KnudsenKA,SingerDE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. ArchInternMed2004;164(8):880-884.Doi: 10.1001/archinte.164.8.880 | |
dc.relation.references | Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GY. Predictive value of the HAS-BLEDand ATRIAbleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143(1):179-184. Doi: 10.1378/chest.12-0608 | |
dc.relation.references | Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. PerformanceoftheHEMORR2HAGES,ATRIAand HAS-BLEDbleedingriskpredictionscoresin anticoagulatedpatientswithatrialfibrillation:The AMADEUSstudy. J Am Coll Cardiol 2013; 61(3): 386 –389. Doi: 10.1016/j.jacc.2012.10.010 | |
dc.relation.references | Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P, European Heart Rhythm Association. Bleeding risk assessment and managementinatrialfibrillationpatients.Executive Summary of a Position Document from the European HeartRhythmAssociation[EHRA],endorsedbythe European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106(6):997-1011. Doi: 10.1160/TH11-10-0690 | |
dc.relation.references | Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ2007; 177(4):347-351. Doi: 10.1503/cmaj.070186 | |
dc.relation.references | Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ2002; 325(7368):828-831 | |
dc.relation.references | Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin initiation in warfarin users andgastrointestinalbleedingrisk.AmJMed 2010;123(2):151-157. Doi: 10.1016/j.amjmed.2009.07.020 | |
dc.relation.references | Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂score. Chest 2013; 144(5):1555-1563. Doi: 10.1378/chest.13-0054 | |
dc.relation.references | Singla DL, Morrill GB. Warfarin maintenance dosages in theveryelderly.AmJHealthSystPharm2005;62 (10):1062-1066 | |
dc.relation.references | Vogel T, Geny B, Kaltenbach G, Lang PO. Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants. Rev Med Interne2015;36(1):22-30.Doi:10.1016/j.revmed. 2014.08.005 | |
dc.relation.references | Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacologicalandpracticalconsiderations.AmJ Cardiovasc Drugs 2014; 14(3):175-189. Doi: 10.1007/ s40256-013-0061-0 | |
dc.relation.references | Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European HeartRhythmAssociation.EuropeanHeartRhythm AssociationPracticalGuideontheuseofneworal anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15(5):625-651. Doi: 10.1093/ europace/ eut083 | |
dc.relation.references | GosselinRC,DwyreDM,DagerWE.Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 2013; 47(12):1635-1640. Doi: 10.1177/1060028013509074 | |
dc.relation.references | Stangier J, Feuring M. Using the HEMOCLOT direct thrombininhibitorassaytodetermineplasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23(2):138-143.Doi:10.1097/MBC. 0b013e32834f1b0c | |
dc.relation.references | Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, HorellouMH,LaporteS,SiguretV,LecompteT. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. Amulticentre French GEHT study. Thromb Haemost 2014; 111(2):240-248. Doi: 10.1160/TH13-06-0470 | |
dc.relation.references | Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62(5):857-864. Doi: 10.1111/jgs.12799 | |
dc.relation.references | Veiga-FernándezF,Malfeito-JiménezMDR,Barros-Cerviño SM, Magariños-Losada MDM. La anticoagulación oral en el anciano con fibrilación auricular no valvular. Rev Esp Geriatr Gerontol 2015; 50(3):134-142. Doi:10.1016/ j.regg.2015.01.005 | |
dc.relation.references | EdholmK,RagleN,RondinaMT.Antithrombotic management of atrial fibrillation in the elderly. Med Clin NorthAm2015;99(2):417-430.Doi:10.1016/j.mcna. 2014.11.012 | |
dc.relation.references | Granziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc 2015; 16(5):358-64. Doi: 10.1016/j.jamda.2014.12.008 | |
dc.relation.references | Lubitz SA, Bauer KA, Benjamin EJ, Besdine RW, Forman DE, Gurol ME, Reddy VY, Singer DE. Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar. J Am Geriatr Soc 2013; 61(10):1798-803. Doi: 10.1111/jgs.12456 | |
dc.relation.references | Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation2007;115(21):2689-2696.Doi:10.1161/ CIRCULATIONAHA.106.653048 | |
dc.relation.references | Zarraga IG, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. J Am Geriatr Soc 2013; 61(1):143-150. Doi: 10.1111/jgs.12042 | |
dc.relation.references | Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patientswithatrialfibrillation.NEnglJMed2011; 365(11):981-992. Doi: 10.1056/NEJMoa1107039 | |
dc.contributor.cvlac | Cadena Sanabria, Miguel Oswaldo [0001339250] | |
dc.contributor.cvlac | Pinto Saavedra, Oscar Mariano [0001692640] | |
dc.contributor.cvlac | Contreras Valero, Juan Fernando [0000121483] | |
dc.contributor.cvlac | Ortega Ramírez, Gustavo Eduardo [0001482931] | |
dc.contributor.googlescholar | Cadena Sanabria, Miguel Oswaldo [jQUx5WcAAAAJ&hl=es&oi=ao] | |
dc.contributor.googlescholar | Pinto Saavedra, Oscar Mariano [DdZsdW4AAAAJ&hl=es&oi=ao] | |
dc.contributor.orcid | Cadena Sanabria, Miguel Oswaldo [0000-0001-9807-3029] | |
dc.contributor.orcid | Pinto Saavedra, Oscar Mariano [0000-0003-1396-0759] | |
dc.subject.lemb | Ciencias medicas | |
dc.subject.lemb | Medicina | |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | |
dc.description.abstractenglish | Aging increases the risk of thrombosis and embolic phenomena. It also brings physiological changes, and comorbidities such as atrial fibrillation that makes complex the onset and safety of anti-clotting. Despite the greater availability of anti-clotting clinics and new oral anticoagulants, the percentage of elderly who are anticoagulated is low, even though they have indications and no contraindications. Objective: To review the main strategies to predict and reduce the risk of bleeding with the use of oral anti-clotting in fragile elderly patients. Methodology: A systematic search was conducted on studies evaluating the safety and efficacy of oral anticoagulants in patients with atrial fibrillation in adults older than 65 years, and a search for studies on the frailty syndrome and its impact on the elderly anticoagulated. Results and Discussion: Fragility has been termed to the percentage of elderly who were diagnosed with a greater deterioration of their biological, physical and cognitive systems, leading to a greater probability of adverse outcomes in health, disability and death. Some clinical features have been studied to identify patients as fragile; Linda Fried's frailty phenotype evaluates these characteristics; furthermore, there are strategies for monitoring oral anticoagulants that should be known to reduce the risk of adverse events. Conclusions: The frail elderly has some risk factors that are likely to affect the efficacy and safety of oral anti-clotting therapy. Existing clinical guidelines do not provide enough evidence and do not consider the elderly patient in a multidimensional manner. | eng |
dc.subject.proposal | Fibrilación atrial | |
dc.subject.proposal | Anciano frágil | |
dc.subject.proposal | Anticoagulantes | |
dc.subject.proposal | Efectos colaterales | |
dc.subject.proposal | Reacciones relacionados con medicamentos | |
dc.subject.proposal | Geriatría | |
dc.identifier.doi | 10.29375/01237047.2273 | |
dc.type.redcol | http://purl.org/redcol/resource_type/ART | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Revista MedUNAB [817]